TY - JOUR
T1 - Disseminated Ureaplasma infection as a cause of fatal hyperammonemia in humans
AU - Bharat, Ankit
AU - Cunningham, Scott A.
AU - Budinger, G. R.Scott
AU - Kreisel, Daniel
AU - DeWet, Charl J.
AU - Gelman, Andrew E.
AU - Waites, Ken
AU - Crabb, Donna
AU - Xiao, Li
AU - Bhorade, Sangeeta
AU - Ambalavanan, Namasivayam
AU - Dilling, Daniel F.
AU - Lowery, Erin M.
AU - Astor, Todd
AU - Hachem, Ramsey
AU - Krupnick, Alexander S.
AU - DeCamp, Malcolm M.
AU - Ison, Michael G.
AU - Patel, Robin
PY - 2015/4/22
Y1 - 2015/4/22
N2 - Hyperammonemia syndrome is a fatal complication affecting immunosuppressed patients. Frequently refractory to treatment, it is characterized by progressive elevations in serum ammonia of unknown etiology, ultimately leading to cerebral edema and death. In mammals, ammonia produced during amino acid metabolism is primarily cleared through the hepatic production of urea, which is eliminated in the kidney. Ureaplasma species, commensals of the urogenital tract, are Mollicutes dependent on urea hydrolysis to ammonia and carbon dioxide for energy production. We hypothesized that systemic infection with Ureaplasma species might pose a unique challenge to human ammonia metabolism by liberating free ammonia resulting in the hyperammonemia syndrome. We used polymerase chain reaction, specialized culture, and molecular resistance profiling to identify systemic Ureaplasma infection in lung transplant recipients with hyperammonemia syndrome, but did not detect it in any lung transplant recipients with normal ammonia concentrations. Administration of Ureaplasmadirected antimicrobials to patients with hyperammonemia syndrome resulted in biochemical and clinical resolution of the disorder. Relapse in one patient was accompanied by recurrent Ureaplasma bacteremia with antimicrobial resistance. Our results provide evidence supporting a causal relationship between Ureaplasma infection and hyperammonemia, suggesting a need to test for this organism and provide empiric antimicrobial treatment while awaiting microbiological confirmation.
AB - Hyperammonemia syndrome is a fatal complication affecting immunosuppressed patients. Frequently refractory to treatment, it is characterized by progressive elevations in serum ammonia of unknown etiology, ultimately leading to cerebral edema and death. In mammals, ammonia produced during amino acid metabolism is primarily cleared through the hepatic production of urea, which is eliminated in the kidney. Ureaplasma species, commensals of the urogenital tract, are Mollicutes dependent on urea hydrolysis to ammonia and carbon dioxide for energy production. We hypothesized that systemic infection with Ureaplasma species might pose a unique challenge to human ammonia metabolism by liberating free ammonia resulting in the hyperammonemia syndrome. We used polymerase chain reaction, specialized culture, and molecular resistance profiling to identify systemic Ureaplasma infection in lung transplant recipients with hyperammonemia syndrome, but did not detect it in any lung transplant recipients with normal ammonia concentrations. Administration of Ureaplasmadirected antimicrobials to patients with hyperammonemia syndrome resulted in biochemical and clinical resolution of the disorder. Relapse in one patient was accompanied by recurrent Ureaplasma bacteremia with antimicrobial resistance. Our results provide evidence supporting a causal relationship between Ureaplasma infection and hyperammonemia, suggesting a need to test for this organism and provide empiric antimicrobial treatment while awaiting microbiological confirmation.
UR - http://www.scopus.com/inward/record.url?scp=84928669364&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.aaa8419
DO - 10.1126/scitranslmed.aaa8419
M3 - Article
C2 - 25904745
AN - SCOPUS:84928669364
SN - 1946-6234
VL - 7
SP - 284ra59
JO - Science translational medicine
JF - Science translational medicine
IS - 284
ER -